The U.S. FDA said Monday that Alnylam Pharmaceuticals' (ALNY) amyloidosis therapy patisiran led to a "small" clinical benefit in a Phase 3.
https://seekingalpha.com/news/4010608-alnylam-amyloidosis-drug-patisiran-small-benefits-fda
The U.S. FDA said Monday that Alnylam Pharmaceuticals' (ALNY) amyloidosis therapy patisiran led to a "small" clinical benefit in a Phase 3.
https://seekingalpha.com/news/4010608-alnylam-amyloidosis-drug-patisiran-small-benefits-fda
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.